Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, participated in ISPOR Europe Health Economics and Market Access conference held from 12-15 November in Copenhagen, Denmark. During this conference, Laurent Décory, COO of Aurealis Therapeutics, presented one of the company’s latest developments: a detailed Markov model used to determine the cost-effectiveness of AUP-16 at healing Diabetic Foot Ulcers (DFUs) when compared to the current Standard of Care (SOC).
The abstract titled A Markov Model to Determine the Cost-Effectiveness of a Multi-Targeting Bacterial Gene Therapy (AUP-16) at Healing a Diabetic Foot Ulcer When Compared to the Current Standard of Care shows that AUP-16 could potentially re-shape the future of DFU treatment. The presented model considered different outcomes including the number of Quality Adjusted Life Years (QALY’s), costs, DFU healing, reoccurrence, death, infections, and amputation. This model found that from a US Medicare and Managed Care perspective, Incremental Cost Effectiveness Ratio (ICER) varied from $3,909/QALY at baseline and $7,434 per QALY, showing that AUP-16 was more cost-effective than the current SOC at healing DFUs.
The abstract and presented poster are now available online on ISPOR’s website.
View the abstract and the poster.
Aurealis Therapeutics remains dedicated to advancing innovative therapies that address unmet medical needs. The team is excited to continue working with clinicians and health economic experts to generate further health economic evidence for AUP-16.
AUP-16 is a genetically engineered Lactococcus Cremoris, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF2, bFGF), interleukin-4 (IL4) and macrophage colony stimulating factor (CSF1, mCSF) – all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective. AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers and pressure ulcers). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product.
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Laurent Décory, COO